Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jul 22;11(1):14948.
doi: 10.1038/s41598-021-94212-6.

Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations

Lyndsey L Anderson  1   2 , Maia G Etchart  2 , Dilara Bahceci  1 , Taliesin A Golembiewski  1 , Jonathon C Arnold  3   4
Affiliations
Comparative Study

Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations

Lyndsey L Anderson et al. Sci Rep. .

Abstract

Cannabis is a complex mixture of hundreds of bioactive molecules. This provides the potential for pharmacological interactions between cannabis constituents, a phenomenon referred to as "the entourage effect" by the medicinal cannabis community. We hypothesize that pharmacokinetic interactions between cannabis constituents could substantially alter systemic cannabinoid concentrations. To address this hypothesis we compared pharmacokinetic parameters of cannabinoids administered orally in a cannabis extract to those administered as individual cannabinoids at equivalent doses in mice. Astonishingly, plasma cannabidiolic acid (CBDA) concentrations were 14-times higher following administration in the cannabis extract than when administered as a single molecule. In vitro transwell assays identified CBDA as a substrate of the drug efflux transporter breast cancer resistance protein (BCRP), and that cannabigerol and Δ9-tetrahydrocannabinol inhibited the BCRP-mediated transport of CBDA. Such a cannabinoid-cannabinoid interaction at BCRP transporters located in the intestine would inhibit efflux of CBDA, thus resulting in increased plasma concentrations. Our results suggest that cannabis extracts provide a natural vehicle to substantially enhance plasma CBDA concentrations. Moreover, CBDA might have a more significant contribution to the pharmacological effects of orally administered cannabis extracts than previously thought.

PubMed Disclaimer

Conflict of interest statement

Associate Professor Arnold has served as an expert witness in various medicolegal cases involving cannabis and cannabinoids and serves as a temporary advisor to the World Health Organization (WHO) on their review of cannabis and the cannabinoids. The remaining authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Pharmacokinetic analysis of orally administered cannabinoids in mouse plasma. Cannabinoids were administered orally as either a full-spectrum cannabis extract or individually at equivalent doses to those in the full-spectrum extract. (a) Dose and profile of cannabinoids within the full-spectrum extract (left panel) vs. the cannabinoids administered individually (right panel). Concentration–time curves for (b) CBDA, (c) CBD (d) CBDVA (e) CBGA (f) Δ9-THC and (f) Δ9-THCA. Concentrations are depicted as both mass concentrations (left y-axis) and molar concentrations (right y-axis) for each cannabinoid administered as a full-spectrum extract (solid symbols) or as an individual compound (open symbols). Data are expressed as means ± SEM, with n = 4–5 per time point.
Figure 2
Figure 2
CBD, CBDA, CBDVA, CBG and Δ9-THC are substrates of BCRP. Concentration–time curves for (a) CBDA, (b) CBD, (c) CBDVA, (d) CBG and (e) Δ9-THC in wildtype (left panel) and BCRP-expressing (middle panel) MDCK cells in the basolateral to apical (B > A) and apical to basolateral (A > B) directions. Right panels represent concentration–time curves for cannabinoids in cells expressing BCRP in the presence of the inhibitor elacridar (dashed lines). Data are expressed as means ± SEM, with n = 4 per time point. Curves represent fits to a linear regression and transport efflux ratios (r) are listed (*p < 0.05, **p < 0.005, ***p < 0.0005 compared to wildtype; Extra sum-of-squares F test).
Figure 3
Figure 3
CBG and Δ9-THC inhibit BCRP-mediated transport of CBDA. Concentration–time curves for CBDA in the presence of (a) vehicle, (b) CBG, (c) Δ9-THC and (d) CBD, (e) CBDVA and (f) a mixture of all four cannabinoids in the basolateral to apical (B > A) and apical to basolateral (A > B) directions in cells expressing BCRP. Cannabinoids were tested at 10 µM. CBG and Δ9-THC significantly inhibit (red shading) transport of CBDA. Data are expressed as means ± SEM, with n = 4 per time point. Curves represent fits to a linear regression and transport efflux ratios (r) are listed (*p < 0.05, ***p < 0.0005, ****p < 0.0001 compared to vehicle; Extra sum-of-squares F test). (g) Schematic of CBDA efflux by BCRP located in the intestinal lumen when administered alone (left panel) or as a full-spectrum cannabis extract where its efflux is inhibited by CBG and Δ9-THC (right panel). Schematic created using BioRender.com.
Figure 4
Figure 4
CBD inhibits BCRP-mediated transport. Concentration–time curves for prazosin in the presence of (a) vehicle, (b) elacridar, (c) CBD (d) CBDA, (e) CBDVA, (f) CBG or (g) Δ9-THC in the basolateral to apical (B > A) and apical to basolateral (A > B) directions in cells expressing BCRP. Elacridar and CBD significantly inhibit (red shading) transport of prazosin. Data are expressed as means ± SEM, with n = 3–4 per time point. Curves represent fits to a linear regression and transport efflux ratios (r) are listed (*p < 0.05, **p < 0.005, ***p < 0.0005 compared to vehicle; Extra sum-of-squares F test).
Figure 5
Figure 5
CBDA inhibits P-glycoprotein-mediated transport. Concentration–time curves for prazosin in the presence of (a) vehicle, (b) loratadine, (c) CBDA (d) CBD, (e) CBDVA, (f) CBG or (g) Δ9-THC in the basolateral to apical (B > A) and apical to basolateral (A > B) directions in cells expressing BCRP. Elacridar and CBD significantly inhibit (red shading) transport of prazosin. Data are expressed as means ± SEM, with n = 3–4 per time point. Curves represent fits to a linear regression and transport efflux ratios (r) are listed (*p < 0.05, compared to vehicle; Extra sum-of-squares F test).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Banister SD, Arnold JC, Connor M, Glass M, McGregor IS. Dark classics in chemical neuroscience: Δ9-tetrahydrocannabinol. ACS Chem. Neurosci. 2019;10:2160–2175. doi: 10.1021/acschemneuro.8b00651. - DOI - PubMed
    1. Oultram JMJ, et al. Cannabis sativa: Interdisciplinary strategies and avenues for medical and commercial progression outside of CBD and THC. Biomedicines. 2021;9:234. doi: 10.3390/biomedicines9030234. - DOI - PMC - PubMed
    1. Formato M, et al. (‒)-Cannabidiolic acid, a still overlooked bioactive compound: An introductory review and preliminary research. Molecules (Basel, Switzerland) 2020 doi: 10.3390/molecules25112638. - DOI - PMC - PubMed
    1. Busardò FP, et al. Disposition of phytocannabinoids, their acidic precursors and their metabolites in biological matrices of healthy individuals treated with vaporized medical cannabis. Pharmaceuticals. 2021 doi: 10.3390/ph14010059. - DOI - PMC - PubMed
    1. Pérez-Acevedo AP, et al. Disposition of cannabinoids and their metabolites in serum, oral fluid, sweat patch and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis. Phyther. Res. 2020 doi: 10.1002/ptr.6931. - DOI - PubMed

Publication types

  NODES
admin 17
COMMUNITY 1
twitter 2